Alps Group Posts 44% Revenue Growth to $4.9M and a Narrower Loss in Fiscal 2026

summarizeSummary

Alps Group posted fiscal 2026 revenue of $4.9 million, up 44% year-over-year, with a reduced net loss of $2.1 million. The company remains in a precarious financial position with negative equity and limited cash, overshadowing operational progress.

check_boxKey Events · Earnings and Guidance · ALPS

• Revenue Jumps 44% to $4.9M

  Fiscal 2026 revenue reached $4.9 million, up from $3.4 million, led by cellular therapy ($883K), medical testing/lab/aesthetics ($3.1M), and healthcare products ($732K).

• Net Loss Narrows to $2.1M

  Net loss improved to $2.1 million from $2.6 million, with gross profit rising to $1.6 million (32% margin) and R&D spending cut to $61K from $170K.

• Precarious Balance Sheet

  Capital deficiencies stood at $3.2 million, with negative equity of $2.9 million attributable to owners. Cash was $607K at year-end, while operating activities consumed $2.6 million.

• Nasdaq Delisting Risk Looms

  The stock trades at $0.42, well below the $1.00 minimum bid requirement flagged by Nasdaq in May 2026. The company has not yet regained compliance.

auto_awesomeAnalysis · ALPS · Industrial Applications And Services

Driven by cellular therapy and medical services, Alps Group delivered strong top-line growth of 44% to $4.9 million, while net loss narrowed to $2.1 million from $2.6 million. Yet the company remains deeply unprofitable, with negative equity of $3.2 million and a cash balance of just $607,000 against $2.6 million in operating cash burn. The results paint a picture of a business in transition—growing revenue but still burning cash and facing Nasdaq delisting risk over its sub-$1 share price. The filing also discloses recent strategic moves, including expanded lab accreditation and a new board appointment, but the financial fragility remains the dominant narrative.